Health knowledge made personal
Join this community!
› Share page:
Search posts:

Dengue Fever Partnering 2007-2012

Posted Dec 11 2012 10:50am
 The Dengue Fever Partnering 2007-2012 provides understanding and access to the dengue fever partnering deals and agreements entered into by the worlds leading healthcare companies.
 The report provides an analysis of dengue fever partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors dengue fever technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 Understanding the flexibility of a prospective partner?s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered ? contract documents provide this insight where press releases do not.
 This data driven report contains over 30 links to online copies of actual dengue fever deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner?s flexibility on a wide range of important issues, many of which will have a significant impact on each party?s ability to derive value from the deal.
 The initial chapters of this report provide an orientation of dengue fever partnering trends.
 Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in dengue fever partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
 Chapter 3 provides an overview of the leading dengue fever deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 Chapter 4 provides a comprehensive directory of dengue fever partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
 In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
 research, development and commercialization of dengue fever technologies and products.
 Report scope
 Dengue Fever Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to dengue fever trends and structure of deals entered into by leading companies worldwide.
 This data driven report includes:
 Trends in dengue fever dealmaking in the biopharma industry since 2007
 Access to summary headline, upfront, milestone and royalty data
 The leading dengue fever deals by value since 2007
 In Dengue Fever Partnering 2007-2012, the available deals are listed by:
 Headline value
 Upfront payment value
 Royalty rate value
 Company A-Z
 Industry sector
 Stage of development at signing
 Deal component type
 Technology type
 Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 For more information kindly visit :
 Bharat Book Bureau
 Tel: +91 22 27810772 / 27810773
 Fax: + 91 22 27812290
 Follow us on twitter:
 Our Blogs:
Post a comment
Write a comment:

Related Searches